Journal
CLINICAL AND VACCINE IMMUNOLOGY
Volume 18, Issue 9, Pages 1586-1588Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/CVI.05107-11
Keywords
-
Categories
Funding
- NICHD [P01 HD 057247-03, U54061221]
- Kettering Family Foundation
- NIH National Center for Research Resources [UL1RR031988, P30HD40677]
- NIH Intellectual and Developmental Disabilities Research Center
- ReGenX Holdings
Ask authors/readers for more resources
Neutralizing antibodies (NAb) to an adeno-associated virus (AAV) vector due to previous natural infection with wild-type AAV can significantly limit gene transfer. NAb titers to AAV serotype 2 (AAV2) and AAV8 in human subjects (0 to 18 years) were studied. NAb prevalence is moderate at birth, decreases markedly from 7 to 11 months, and then progressively increases through childhood and adolescence.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
